<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600089</url>
  </required_header>
  <id_info>
    <org_study_id>60617</org_study_id>
    <nct_id>NCT04600089</nct_id>
  </id_info>
  <brief_title>Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI</brief_title>
  <acronym>2020Ketamine</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Study to Identify the Opioid-sparing Effects, and Pain-reduction Potential of Low Dose Ketamine on Patients Undergoing TEVAR Procedures Receiving NCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Rockich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify the opioid-sparing effects, and pain-reduction&#xD;
      potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular&#xD;
      aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing descending aortic repair often experience post-operative pain, and have&#xD;
      high post operative opioid requirements. That pain is partially due to the use of naloxone&#xD;
      continuous infusion (NCI). NCI is part of a bundled approach used in the first 48 hours&#xD;
      post-operatively to prevent spinal cord ischemia, a devastating complication associated with&#xD;
      surgical repair of the descending aortic. Data indicate that patients receiving NCI&#xD;
      experience elevated post-operative pain scores and increased opioid requirements during the&#xD;
      48-hr post-operative NCI administration, compared to patients not receiving NCI.&#xD;
&#xD;
      Ketamine is an FDA-approved N-methyl D-aspartate (NMDA) antagonist that has been shown to&#xD;
      provide adjunctive analgesia and opioid-sparing effects in post-operative surgical patients.&#xD;
      At low doses, ketamine provides analgesic benefit without the anesthetic effects seen at&#xD;
      higher doses. These doses are commonly referred to sub-dissociative. This study will evaluate&#xD;
      whether use of sub dissociative ketamine (SDK) in patients undergoing aortic procedures with&#xD;
      the use of NCI will lead to decreased post-operative opioid consumption, and produce improved&#xD;
      pain scores in the first 48 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Opioid Dose</measure>
    <time_frame>48 hours</time_frame>
    <description>Total morphine milligram equivalents (MME) will be assessed every 6 hours for 48 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain will be assessed using a 10-Point Numerical Pain Scale (as part of standard of care) every hour for the first 24 hours and every two hours for the next 24 hours. Scores range from 0-10; higher scores indicated higher levels of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Ketamine-Induced Delirium</measure>
    <time_frame>48 hours</time_frame>
    <description>Ketamine-induced delirium will be monitored via the Confusion Assessment Method (CAM-ICU) survey every 8 hours for 48 hours. The CAM-ICU assesses four diagnostic features of delirium and the result is a binary (yes or no) determination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Uncontrolled Hypertension</measure>
    <time_frame>48 hours</time_frame>
    <description>Uncontrolled hypertension is defined as a systolic pressure of 160 mmHg despite 3 intravenous antihypertensive agents.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Descending Aortic Dissection</condition>
  <condition>Postoperative Pain</condition>
  <condition>Thoracoabdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive standard of care as well as a saline infusion during the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Dissociative Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline infusion</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.</description>
    <arm_group_label>Sub-Dissociative Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  willing to give informed consent&#xD;
&#xD;
          -  scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair&#xD;
&#xD;
          -  requires naloxone continuous infusion for spinal prophylaxis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to ketamine, acetaminophen, or fentanyl&#xD;
&#xD;
          -  diagnosis of schizophrenia&#xD;
&#xD;
          -  history of hydrocephalus or central nervous system mass&#xD;
&#xD;
          -  incarcerated individuals&#xD;
&#xD;
          -  pregnant or lactating individuals&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Rockich, Pharm D</last_name>
    <role>Study Director</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Johnson, PharmD</last_name>
    <phone>8593235722</phone>
    <email>eric.johnson@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Johnson, PharmD</last_name>
      <phone>859-323-5722</phone>
      <email>eric.johnson@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Anna Rockich</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>naloxone</keyword>
  <keyword>ketamine</keyword>
  <keyword>aortic repair</keyword>
  <keyword>spinal cord ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aneurysm, Dissecting</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

